TY - JOUR
T1 - Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy
AU - De Sanctis, Roberto
AU - Pane, Marika
AU - Coratti, Giorgia
AU - Palermo, Concetta
AU - Leone, Daniela
AU - Pera, Maria Carmela
AU - Abiusi, Emanuela
AU - Fiori, Stefania
AU - Forcina, Nicola
AU - Fanelli, Lavinia
AU - Lucibello, Simona
AU - Mazzone, Elena S.
AU - Tiziano, Francesco Danilo
AU - Mercuri, Eugenio Maria
PY - 2018
Y1 - 2018
N2 - The advent of clinical trials has highlighted the need for natural history studies reporting disease progression in type 1 spinal muscular atrophy. The aim of this study was to assess functional changes using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) scale in a cohort of type 1 infants. Nutritional and respiratory longitudinal data were also recorded. Patients were classified according to the severity of the phenotype and age of onset. SMN2 copies were also assessed. Twenty patients were included, eight with early onset most severe phenotype, eight with the more typical type 1 phenotype and 4, who achieved some head control, with a milder phenotype. Both baseline values and trajectories of progression were different in the three subgroups (p = 0.0001). Infants with the most severe phenotype had the lowest scores (below 20) on their first assessment and had the most rapid decline. Those with the typical phenotype had scores generally between 20 and 40 and also had a fast decline. The infants with the milder phenotype had the highest scores, generally above 35, and a much slower deterioration. Infants with three SMN2 copies had an overall milder phenotype and milder progression while two SMN2 copies were found in all three subgroups.
AB - The advent of clinical trials has highlighted the need for natural history studies reporting disease progression in type 1 spinal muscular atrophy. The aim of this study was to assess functional changes using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) scale in a cohort of type 1 infants. Nutritional and respiratory longitudinal data were also recorded. Patients were classified according to the severity of the phenotype and age of onset. SMN2 copies were also assessed. Twenty patients were included, eight with early onset most severe phenotype, eight with the more typical type 1 phenotype and 4, who achieved some head control, with a milder phenotype. Both baseline values and trajectories of progression were different in the three subgroups (p = 0.0001). Infants with the most severe phenotype had the lowest scores (below 20) on their first assessment and had the most rapid decline. Those with the typical phenotype had scores generally between 20 and 40 and also had a fast decline. The infants with the milder phenotype had the highest scores, generally above 35, and a much slower deterioration. Infants with three SMN2 copies had an overall milder phenotype and milder progression while two SMN2 copies were found in all three subgroups.
KW - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders
KW - Genetics (clinical)
KW - Neurology
KW - Neurology (clinical)
KW - Neuromuscular disorders
KW - Outcome measures
KW - Pediatrics, Perinatology and Child Health
KW - Spinal Muscular Atrophy
KW - Werdnig-Hoffman disease
KW - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders
KW - Genetics (clinical)
KW - Neurology
KW - Neurology (clinical)
KW - Neuromuscular disorders
KW - Outcome measures
KW - Pediatrics, Perinatology and Child Health
KW - Spinal Muscular Atrophy
KW - Werdnig-Hoffman disease
UR - http://hdl.handle.net/10807/134555
UR - http://www.elsevier.com/locate/nmd
U2 - 10.1016/j.nmd.2017.09.015
DO - 10.1016/j.nmd.2017.09.015
M3 - Article
SN - 0960-8966
VL - 28
SP - 24
EP - 28
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
ER -